Toripalimab

Toripalimab is a humanized monoclonal antibody and an immune checkpoint inhibitor used in the treatment of certain cancers. It belongs to the programmed cell death protein 1 (PD-1) inhibitor class of medicines. PD-1 is a receptor found on immune cells, particularly T cells, that helps regulate immune responses. Some cancer cells use the PD-1 pathway to reduce immune system activity and avoid being recognized and attacked. Toripalimab binds to PD-1 and blocks its interaction with its ligands, PD-L1 and PD-L2, helping restore antitumour immune activity. It is administered by intravenous infusion under the supervision of trained healthcare professionals. Depending on the approved indication and treatment protocol, it may be used alone or in combination with chemotherapy. Its established clinical role includes the treatment of nasopharyngeal carcinoma, a cancer arising in the upper part of the throat behind the nose, and certain forms of esophageal squamous cell carcinoma. Like other immune checkpoint inhibitors, toripalimab can cause the immune system to attack healthy organs and tissues, sometimes resulting in serious complications. Treatment selection therefore requires assessment of the cancer type, previous therapies, general health, and potential risks. Regular clinical and laboratory monitoring is important throughout treatment.

Toripalimab was developed as an immunotherapy targeting the PD-1 pathway, with clinical research evaluating its activity in several solid tumours. Its development included the JUPITER-02 clinical trial, which investigated toripalimab with cisplatin and gemcitabine for recurrent or metastatic nasopharyngeal carcinoma, and other studies examining its use in different cancers. The United States Food and Drug Administration (FDA) approved toripalimab-tpzi on 27 October 2023 for specified nasopharyngeal carcinoma indications, including first-line treatment in combination with cisplatin and gemcitabine and treatment of certain previously treated cases as monotherapy. The European Commission granted marketing authorisation for toripalimab under the name Loqtorzi in September 2024, with authorised indications including nasopharyngeal carcinoma and esophageal squamous cell carcinoma in specified chemotherapy combinations. In India, the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has authorised toripalimab for specified cancer indications. In October 2026, an additional Indian approval was announced for first-line treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma in combination with cisplatin and paclitaxel. Approved indications and treatment protocols differ by jurisdiction and should be verified against the applicable prescribing information.

Toripalimab is used for specific cancers according to the regulatory approval and treatment guidelines applicable in each country. In the United States, it is indicated with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. It is also approved as monotherapy for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that has progressed during or after platinum-containing chemotherapy. In the European Union, authorised uses include first-line treatment of recurrent nasopharyngeal carcinoma that cannot be treated with surgery or radiotherapy, or metastatic disease, in combination with cisplatin and gemcitabine. Its European authorisation also includes first-line treatment of unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma in combination with cisplatin and paclitaxel. In India, authorised indications include specified treatment settings for nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Toripalimab is not a general treatment for all cancers, and its use in other tumour types depends on applicable approvals and clinical evidence. Treatment decisions should consider tumour type, disease stage, previous treatment, patient fitness, and the locally approved prescribing information.

Toripalimab is administered by intravenous infusion in a clinical setting. The recommended regimen depends on the cancer being treated and whether the medicine is given alone or with chemotherapy. Under the United States prescribing information, the recommended dose for first-line nasopharyngeal carcinoma in combination with cisplatin and gemcitabine is 240 mg every three weeks, generally for up to 24 months or until disease progression or unacceptable toxicity. For specified previously treated nasopharyngeal carcinoma, the recommended monotherapy dose is 3 mg/kg every two weeks, continued until disease progression or unacceptable toxicity. In authorised European and other regional protocols, dosing for esophageal squamous cell carcinoma is determined by the applicable product information and chemotherapy schedule; the regimen should not be assumed to be interchangeable with the nasopharyngeal carcinoma monotherapy schedule. The first infusion generally takes about 60 minutes, and subsequent infusions may be shortened according to the prescribing information if the initial infusion is tolerated. Dose reductions are generally not recommended under the US label; treatment may instead be withheld or permanently discontinued for specified toxicities. The treating oncologist should determine the regimen, duration, and any treatment interruptions.

Common side effects of toripalimab vary according to the cancer indication and whether chemotherapy is given concurrently. When combined with cisplatin and gemcitabine for nasopharyngeal carcinoma, reported effects include nausea, vomiting, reduced appetite, constipation, diarrhoea, rash, fever, cough, fatigue or general discomfort, muscle and joint pain, dizziness, insomnia, upper respiratory infections, peripheral neuropathy, and hypothyroidism. When used alone for previously treated nasopharyngeal carcinoma, fatigue, hypothyroidism, and musculoskeletal pain are among the most common adverse reactions. Chemotherapy may contribute additional effects, making it important to assess symptoms in the context of the full regimen. Some effects can be managed with supportive treatment, dose scheduling changes, or treatment of the underlying cause under medical supervision. Patients should report persistent or worsening symptoms, especially diarrhoea, unusual tiredness, skin changes, or symptoms suggestive of altered thyroid function. Side effects should not be dismissed simply because they begin several weeks or months after treatment starts.

Toripalimab can cause serious or potentially life-threatening immune-mediated reactions because it increases immune activity against cancer cells but may also affect healthy tissues. Important complications include pneumonitis, or inflammation of the lungs; colitis, or inflammation of the bowel; hepatitis; thyroid and other endocrine disorders; nephritis and kidney dysfunction; and severe skin reactions. Less common but important risks can include inflammation affecting the heart, nervous system, or other organs. Infusion-related reactions may also occur. In some patients, immune-related effects can appear after treatment has been discontinued. New or worsening breathlessness, persistent diarrhoea, severe abdominal pain, jaundice, reduced urine output, unusual weakness, confusion, or extensive skin blistering requires prompt medical assessment. Depending on the type and severity of an adverse reaction, treatment may need to be withheld or permanently discontinued, and corticosteroids or other immunosuppressive treatment may be required. Toripalimab can also increase the risk of complications in patients undergoing allogeneic haematopoietic stem-cell transplantation. It may cause fetal harm, so pregnancy-related risks and appropriate contraception should be discussed before treatment. Patients should receive the medicine only under specialist supervision with a plan for recognising and managing immune-related toxicity.

Before starting toripalimab, clinicians should review the patient's medical history, previous cancer treatments, autoimmune disorders, organ transplantation history, current medicines, and pregnancy or breastfeeding status where relevant. Baseline assessment generally includes liver enzymes, kidney function, thyroid function, and other investigations guided by the patient's condition and treatment regimen. These assessments should be repeated periodically during treatment. Patients with active autoimmune disease or a history of organ transplantation may require particularly careful evaluation because immune checkpoint inhibition can aggravate autoimmune conditions or contribute to transplant rejection. Patients receiving systemic immunosuppressants, including corticosteroids, require individual assessment, although corticosteroids may be necessary to manage immune-mediated adverse reactions. Live vaccines should generally be avoided during treatment unless specifically advised under applicable clinical guidance; vaccination timing should be discussed with the treating team. Toripalimab is a monoclonal antibody and is not expected to have the same conventional metabolic drug interactions as many small-molecule medicines. However, concomitant medicines, chemotherapy, immune-modifying therapies, and other cancer treatments can affect overall safety and should be reviewed. Pregnancy should be avoided during treatment and for the recommended period after the last dose, according to the applicable product information. Breastfeeding is generally not recommended during treatment and for the specified period after the final dose.

Confirm the tumour type, disease stage, prior treatment history, and locally approved indication before initiating toripalimab. Verify the correct dose, infusion interval, and accompanying chemotherapy regimen against the relevant prescribing information, as schedules differ between indications and jurisdictions. Obtain baseline liver, kidney, and thyroid function tests, and arrange ongoing monitoring throughout treatment. Educate patients and caregivers about immune-mediated reactions and explain that symptoms can develop during treatment or after its completion. Establish a clear pathway for urgent clinical review when new respiratory symptoms, persistent diarrhoea, abdominal pain, jaundice, neurological changes, or marked weakness occurs. Review concomitant medicines, autoimmune conditions, transplantation history, and planned vaccinations before treatment. Administer the infusion in an appropriately equipped setting, monitor for infusion-related reactions, and follow the product-specific storage, preparation, and handling instructions. When toripalimab is combined with chemotherapy, distinguish potential immune-mediated toxicities from chemotherapy-related adverse effects wherever possible. Document treatment interruptions, immunosuppressive management, and the criteria for restarting or permanently discontinuing therapy. Coordinate care among oncology, nursing, pharmacy, and relevant specialist teams to support safe administration and timely toxicity management.